阿司匹林联合华法林对冠心病合并心房纤颤患者的安全性和有效性分析

Safety and efficacy of aspirin combined with warfarin in the treatment of coronary heart disease and atrial fibrillation

目的观察阿司匹林联合华法林对冠心病合并心房纤颤的有效性和安全性。方法回顾性分析2012年8月至2013年8月46例来我科住院治疗的冠心病合并心房纤颤患者,分为观察组(阿司匹林和华法林联合治疗)和对照组(华法林单药治疗),每组23例。随访1年,比较两组血栓栓塞发生率、出血发生率及患者的肾功能。结果观察组患者血栓栓塞发生率、出血发生率及肾功能各项指标与对照组比较,差异无统计学意义(P>0.05)。结论阿司匹林联合华法林治疗冠心病合并房颤的脑血栓发生率较低,出血风险较小,对肾功能也没有严重损害,但与华法林单药治疗比较,差异无统计学意义。

Objective To observe the safety and efficacy of aspirin combined with warfarin in the treatment of coronary heart disease and atrial fibrillation. Methods 46 cases of patients with coronary heart disease and atrial fibrillation in our department from August 2012 to August 2013 were divided into observation group and control group,23cases in each group. The observation group received aspirin combined with warfarin treatment,the control group received warfarin treatment only. The incidence of thromboembolism,bleeding,and renal function of the two groups were compared. Results The incidene of thromboembolism,bleeding,and renal function changes had no significant differences between observation group and control group（ P ＆gt; 0. 05）. Conclusion Aspirin combined with warfarin treatment for coronary heart disease and atrial fibrillation has lower incidence of thrombosis,bleeding,but has no significant difference compared with warfarin alone.